LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the expansion of the Company's research partnership with Children's Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors for a range of gene therapy and gene editing applications in the treatment of serious diseases of the liver and two other tissues.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET. Mr. Chereau will provide an overview of company operations including development of its proprietary genome editing platform GeneRide and its next-generation synthetic capsids. He will also participate in one-on-one sessions with investors during the virtual conference.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021. Matthias Jaffe, the current CFO at LogicBio, will step down at the end of the year and will remain a consultant to the Company during 2021.